Answers are grounded in this paper and cite their sources.
We evaluated dermatological adverse events (dAEs) associated with amivantamab in 57 patients treated at a tertiary oncology referral centre. dAEs occurred in all patients and were frequently multiple and high-grade, with over one-third of patients requiring modification of oncological treatment. Dermatology-guided management resulted in clinical improvement in the majority of patients, underscoring the importance of early dermatological involvement and longitudinal follow-up during amivantamab therapy.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: